Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP).

被引：0
|
作者：
Fleming, M. T.
Pond, G. R.
Armstrong, A. J.
Wood, B. A.
Brookes, M.
Leopold, L. H.
Matveev, V. B.
Burke, J. M.
Caton, J. R.
Sonpavde, G.
机构：
[1] US Oncol Res, The Woodlands, TX USA
[2] Virginia Oncol Associates, Hampton, VA USA
[3] McMaster Univ, Hamilton, ON, Canada
[4] Duke Canc Inst, Durham, NC USA
[5] Ascenta Therapeut, Malvern, PA USA
[6] Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Moscow, Russia
[7] Rocky Mt Canc Ctr, Aurora, CO USA
[8] Willamette Valley Canc Ctr, Eugene, OR USA
[9] Baylor Coll Med US Oncol Res, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e15019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15019
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Docetaxel chemotherapy in metastatic castration-resistant prostate cancer (mCRPC): Cost of care for Medicare and commercially insured men.
    Armstrong, Andrew J.
    Bui, Cat N.
    Fitch, Kate
    Sawhney, Tia
    Brown, Bruce
    Flanders, Scott C.
    Francis, Peter St. John
    Balk, Mark A.
    Deangelis, Julie
    Chambers, James
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [32] Characterizing longitudinal molecular changes in ctDNA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tran, Eli
    Jani, Chinmay
    Zhang, Nicole
    Tsai, Jill
    Pan, Elizabeth
    Panian, Justine
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 205 - 205
  • [33] A deep learning framework (DLF) to identify clinical predictors of disease progression and mortality in metastatic castration-resistant prostate cancer (mCRPC) patients treated with docetaxel/prednisone (DP).
    Maria Galmarini, Carlos
    Dominguez Correa, Juan Manuel
    Gomez del Campo, Pablo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).
    Halabi, Susan
    Dutta, Sandipan
    Araujo, John C.
    Logothetis, Christopher
    Sternberg, Cora N.
    Armstrong, Andrew J.
    Carducci, Michael Anthony
    Chi, Kim N.
    De Bono, Johann S.
    Petrylak, Daniel Peter
    Fizazi, Karim
    Higano, Celestia S.
    Small, Eric Jay
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Overall survival of men with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line docetaxel-containing chemotherapy according to their participation (or not) in clinical trials.
    Goyal, Jatinder
    Huang, Peng
    Tyagi, Prachi
    Oh, Daniel
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [36] Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials.
    Sonpavde, Guru
    Pond, Gregory Russell
    Templeton, Arnoud J.
    Kwon, Eugene D.
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [37] Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC)
    Tannock, Ian
    Fizazi, Karim
    Ivanov, Sergey
    Thellenberg-Karlsson, Camilla
    Flechon, Aude
    Skoneczna, Iwona Anna
    Orlandi, Francisco Jorquera
    Gravis, Gwenaelle
    Matveev, Vsevolod
    Bavbek, Sevil E.
    Gil, Thierry
    Viana, Luciano S.
    Aren, Osvaldo
    Karyakin, Oleg
    Elliott, Tony
    Birtle, Alison J.
    Magherini, Emmanuelle
    Petrylak, Daniel Peter
    Tombal, Bertrand
    Rosenthal, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401
    Kelly, W. K.
    Halabi, S.
    Carducci, M. A.
    George, D. J.
    Mahoney, J. F.
    Stadler, W. M.
    Morris, M. J.
    Kantoff, P. W.
    Monk, J. P., III
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [39] The Effect of Therapeutic Anticoagulation on Overall Survival in Men Receiving First-Line Docetaxel Chemotherapy for Metastatic Castration-Resistant Prostate Cancer
    Park, Jong Chul
    Pratz, Caroline F.
    Tesfaye, Anteneh
    Brodsky, Robert A.
    Antonarakis, Emmanuel S.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (01) : 32 - 38
  • [40] Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC)
    Pond, G. R.
    Armstrong, A. J.
    Wood, B. A.
    Brookes, M.
    Leopold, L. H.
    Burke, J. M.
    Caton, J. R.
    Fleming, M. T.
    Sonpavde, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
12345